Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark; Center for Experimental Neuroscience, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Anesthesiology, Aarhus University Hospital, Aarhus, Denmark.
Neuromodulation. 2022 Jul;25(5):700-709. doi: 10.1016/j.neurom.2022.03.001. Epub 2022 Apr 5.
Spinal cord stimulation (SCS) is a surgical treatment modality reserved for a subset of patients with neuropathic pain in which conventional pharmacologic treatment has proven insufficient. Previous studies have suggested a possible negative relationship between opioid use at referral and subsequent success of SCS therapy. The aim of this cohort study was to investigate whether preoperative opioid use was associated with inferior SCS outcomes.
Data were obtained from the Danish Neurizon Neuromodulation Database and comprised preoperative registrations of analgesic use, postoperative Patients' Global Impression of Change (PGIC) ratings, pre- and postoperative pain intensity scores (Numeric Rating Scale), and detailed surgical data. Patients were dichotomized according to preoperative opioid use (users vs nonusers) with subsequent assessment of the latest PGIC rating, reduction in pain intensity, and current treatment status (implanted/explanted). In addition, daily preoperative opioid dosages were quantified in oral morphine equivalents (OME) and correlated to the treatment outcomes.
A total of 467 patients were included; 296 consumed opioids before SCS implantation (median 80 OME/d). Preoperative opioid use was not associated with the latest PGIC rating, reduction in pain intensity (30% or 50%), or risk of undergoing explantation (median follow-up = 3.0 years). Likewise, preoperative median OME per day of opioid users was not correlated with any of the defined outcomes.
Preoperative opioid usage did not predict the outcome of SCS therapy in a large cohort of patients permanently implanted with an SCS system. The results do not support withholding otherwise well-indicated SCS therapy in patients with chronic neuropathic pain conditions based merely on preoperative opioid usage.
脊髓刺激(SCS)是一种手术治疗方式,仅适用于经证实常规药物治疗无效的神经性疼痛患者亚组。先前的研究表明,在转诊时使用阿片类药物与 SCS 治疗的后续成功之间可能存在负相关关系。本队列研究旨在调查术前使用阿片类药物是否与 SCS 结果较差相关。
数据来自丹麦 Neurizon 神经调节数据库,包括术前镇痛药物使用登记、术后患者整体印象变化(PGIC)评分、术前和术后疼痛强度评分(数字评分量表)以及详细的手术数据。患者根据术前是否使用阿片类药物(使用者与非使用者)进行分类,随后评估最新的 PGIC 评分、疼痛强度的降低以及当前的治疗状况(植入/取出)。此外,还量化了术前每日阿片类药物剂量(口服吗啡当量,OME),并将其与治疗结果相关联。
共纳入 467 例患者;296 例在 SCS 植入前使用阿片类药物(中位数 80 OME/d)。术前使用阿片类药物与最新的 PGIC 评分、疼痛强度降低(30%或 50%)或进行取出的风险无关(中位数随访时间=3.0 年)。同样,阿片类药物使用者术前每日 OME 的中位数与任何定义的结局均无相关性。
在永久性植入 SCS 系统的大量患者中,术前阿片类药物的使用并不能预测 SCS 治疗的结果。这些结果不支持仅仅基于术前阿片类药物的使用来拒绝对慢性神经性疼痛患者进行有指征的 SCS 治疗。